Skip to Content

Titanium IBR (Canada)

This page contains information on Titanium IBR for veterinary use.
The information provided typically includes the following:
  • Titanium IBR Indications
  • Warnings and cautions for Titanium IBR
  • Direction and dosage information for Titanium IBR

Titanium IBR

This treatment applies to the following species:
Manufacturer: Elanco

Bovine Rhinotracheitis Vaccine

Modified Live Virus

IBR

CONTENTS:

Infectious Bovine Rhinotracheitis Virus (IBR), Modified Live Virus

PRODUCT DESCRIPTION:

Titanium® IBR contains desiccated Bovine Rhinotracheitis Virus Vaccine and sterile diluent to rehydrate the vaccine. Titanium® IBR is a modified live vaccine to be used as an aid in the prevention of disease caused by infectious bovine rhinotracheitis virus (IBR).

The desiccated fraction contains no bovine serum, which reduces the risk of extraneous virus contamination and possible allergic reactions. Control animals, housed with vaccinates, remained seronegative throughout the testing period.

EFFICACY:

Efficacy was demonstrated by vaccination and challenge studies. Following vaccination, seroconversion occurred in 81% of the calves receiving a single vaccination, and 100% after 2nd vaccination. Following challenge, vaccinated animals exhibited significant reduction of morbidity and clinical signs. In contrast, unvaccinated challenged calves exhibited clinical signs of extended duration, increased severity and extended virus shedding.

IMMUNE RESPONSES:

Research demonstrated Titanium® IBR is safe and efficacious however; individual animals may be unable to develop an adequate immune response following vaccination due to: concurrent disease, malnutrition, parasitism, or stress due to shipment or environmental conditions.

SAFETY:

Safety in pregnant heifers and cows was demonstrated in trials conducted at three separate sites. The heifers and cows were vaccinated prior to breeding with Titanium® 5 L5 HB, followed by a post-breeding vaccination at the first, second or third trimester of pregnancy. The cows were observed from pregnancy vaccination through calving for fetal loss. Heifers and cows vaccinated with Titanium® 5 L5 HB had abortions and calving rates similar to the control cows.

Calving Rates (normal calves delivered/total deliveries)

Trimester

Controls

Vaccinates

1

205/213 (96.24%)

201/209 (96.17%)

2

295/310 (95.16%)

305/315 (96.83%)

3

197/208 (94.71%)

198/205 (96.59%)

Total

697/731 (95.35%)

704/729 (96.57%)

The fetal loss in the two groups was similar with 3.43% in the Titanium® 5 L5 HB vaccinated groups and 4.65% in the control groups. Following calving, each calf’s health was monitored for 4 weeks. The health of the calves in the Titanium® 5 L5 HB vaccinated dams was similar to the health of calves born to the control dams. WARNING: Fetal health risks associated with vaccination of pregnant animals with modified live vaccines cannot be unequivocally determined by clinical trials conducted for licensure. Vaccination of pregnant animals with modified live vaccines should be discussed with a veterinarian.

INDICATIONS FOR USE:

Titanium® IBR is recommended for the vaccination of healthy cows and heifers, no less than 30 days prior to breeding, as an aid in the prevention of disease caused by infectious bovine rhinotracheitis virus (IBR). Titanium® IBR may be administered to pregnant cattle provided they were vaccinated, according to label directions, with any Titanium product containing infectious bovine rhinotracheitis virus and bovine virus diarrhea virus 30 to 60 days prior to breeding. To help ensure safety in pregnant cattle, heifers must receive at least two doses of any Titanium product containing IBR-BVD, with the second dose administered approximately 30 days prebreeding. Titanium® IBR may also be administered to calves nursing pregnant cows provided their dams were vaccinated as described above.

Dosage and Administration

Rehydrate the desiccated vial with accompanying diluent and shake well. Inject 2 mL subcutaneously using aseptic technique. Annual revaccination is recommended. Calves vaccinated before weaning should be revaccinated 30 days after weaning when the possible influence of maternal antibodies is decreased.

CAUTIONS:

Recommended for the vaccination of healthy cows and heifers no less than 30 days prior to breeding. Titanium® IBR may be administered to pregnant cattle provided they were vaccinated, according to label directions, with any Titanium product containing IBR and BVD 30 to 60 days prior to breeding. To help ensure safety in pregnant cattle, heifers must receive at least two doses of any Titanium product containing IBR-BVD, with the second dose administered approximately 30 days prebreeding. Failure to follow label directions may result in abortions. The Titanium® line may be administered to calves nursing pregnant cows provided their dams were vaccinated as described above. Store at 2° to 8° C. DO NOT FREEZE. Use entire contents when first opened. Allergic reactions may follow the use of vaccines. ANTIDOTE: Epinephrine. Do not vaccinate within 21 days before slaughter. Burn container and all unused contents.

FOR USE IN ANIMALS ONLY

SUPPLIED:

Code:

AV 4165

10 dose (20 mL)

50 per case

AV 4165

50 dose (100 mL)

20 per case

Manufactured by: Diamond Animal Health, Inc., Des Moines, Iowa 50327 U.S.A.

U.S. Veterinary License No. 213

Distributed by: Elanco, Division Eli Lilly Canada, Inc., Guelph, ON, N1G 4T2 Canada

1-800-265-5475

02301

NAC No.: 1184053.0

ELANCO, Division Eli Lilly Canada Inc. & ELANCO CANADA LIMITED (successor to Novartis Animal Health Canada Inc.)
RESEARCH PARK CENTRE, 150 RESEARCH LANE, SUITE 120, GUELPH, ON, N1G 4T2
Telephone:   519-821-0277
Order Desk:   800-773-7603
Fax:   519-821-7831
Elanco Canada Limited Customer Service Telephone:   800-387-6325
Elanco Canada Limited Customer Service Fax:   800-827-5782
Website:   www.Elanco.ca
Every effort has been made to ensure the accuracy of the Titanium IBR information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the Canadian product label or package insert.

Copyright © 2016 North American Compendiums. Updated: 2016-08-21

Hide